Sonntag, 24. Januar 2021
Navigation öffnen


Comparison Between Endovascular and Bronchoscopic Tumor Marker Insertion for Real-time Stereotactic-guided Radiotherapy in Lung Cancer



Oktober 2016

Letztes Update:


Indikation (Clinical Trials):
Lung Neoplasms


Erwachsene (18+)


Centre Hospitalier Universitaire Vaudois



Studienlocations (1 von 1)

Centre Hospitalier Universitaire vaudois - Department of Radiology and Interventional Radiology
1011 Lausanne
SwitzerlandRekrutierend» Google-Maps
Rafael DURAN
Phone: +41213144444
» Ansprechpartner anzeigen


Brief Summary:

The role of radiotherapy is well established in the management of early stage lung cancer or

as part of a multidisciplinary approach of locally advanced lung cancer (1).

Recent advances in Cyberknife© technology, which is a robotic system of stereotactic

irradiation including localisation and real time lesion-tracking, has led to an increase in

accuracy and potentially in efficiency of the irradiation of tumor field (2)(3). According to

several studies, promising results in local control and survival rates have been achieved in

patients suffering from primary lung cancer or peripheral lung metastasis treated with

Cyberknife© (4)(5)(6)(7)(8).

Fiducial markers are implanted in or near a tumor in a configuration defining a COM (center

of mass) guiding the Cyberknife for tumor localization.

Tumor movement is then synchronized to respiratory cycle motion during treatment which

reduces toxicity of non target lung tissue irradiation. Change in marker positioning leads to

COM alterations, thus limiting detection by the tracking system.

Percutaneous (9)(10)(11) (12), endovascular (12)(13) fiducial implantation or by means of

bronchoscopic devices (14)(15)(16)(17)(18) are three techniques that have been validated in

previous studies as feasible and safe procedures, providing accurate tracking.

Few studies are currently available in the litterature comparing these modalities (19)(20).

The percutaneous implantation technique will not be considered for this study because this

technique is associated with a high risk of pneumothorax (9).

Both the endobronchial and endovascular technique have been described in the literature with

equivalent success rate (87-90%) in intention to treat (21)(22).

One of the endpoints of this study is to verify that these results are reproducible in our

institution where both techniques are currently available and to investigate other secondary

endpoints such as fiducial marker migration after placement, complications rates and

procedure time.


Inclusion Criteria:

- Lung cancer (primary or secondary, any histological type)

- Early stage lung cancer: patients diagnosed with stage I for which operation is

contra-indicated, for example because of cardiac or pulmonary comorbidities.

- Locally advanced lung cancer stages II - IIIB

- Metastatic lung cancer stage IV (palliative care)

- 18 y ≤ age ≤ 85 y

Exclusion Criteria:

- age <18y

- incapacity of judgment

- Absence of a signed consent form


Primary outcome:

1. Cyberknife© tracking (Time Frame - Before Cyberknife):
Tumor tracking assessment by Cyberknife© after bronchoscopic and endovascular fiducial marker implantation

Secondary outcome:

1. Fiducial implantation evaluation by operator (Time Frame - Immediately post-implantation):
Assessment of technical feasibility of implantation of at least three fiducial markers around the lung tumor in both techniques

2. Fiducial marker migration (Time Frame - Immediately post-implantation and before Cyberknife):
Secondary fiducial migration rate assessment in both techniques

3. Procedure time (Time Frame - Immediately after the procedure):
Procedure time required for the implantation of three markers around the lung tumor in both techniques

4. Complication rate (Time Frame - within 30 days of fiducial marker placement):
Complication rate (AE/SEA) within 30 days of fiducial marker placement in both techniques


  • Endovascular fiducial marker insertion
    Fiducial markers are inserted and released near the tumor through femoral puncture. A catheter is led through the venous system to the right heart and from there through the heart into the pulmonary arteries.
  • Bronchoscopic fiducial marker insertion
    Fiducial markers are inserted and released near the tumor into the bronchi using an endoscopic route

Geprüfte Regime

  • Endovascular fiducial marker insertion:
    Fiducial markers will be inserted using an endovascular route
  • Bronchoscopic fiducial marker insertion:
    Fiducial markers will be inserted using an endoscopic route


ASH 2020
  • Phase-III-Studie ASCEMBL bei resistenten/intoleranten Patienten mit CML: STAMP-Inhibitor Asciminib deutlich effektiver als TKI Bosutinib
  • Ruxolitinib-resistente/-intolerante MF-Patienten profitieren im klinischen Alltag möglicherweise von einer Rechallenge
  • Real-world-Daten zu PV: Rechtzeitige Umstellung von HU auf Ruxolitinib wirkt möglicherweise Anstieg thromboembolischer Ereignisse entgegen
  • 5-Jahres-Daten der RESPONSE-2-Studie: Überlegenheit von Ruxolitinib gegenüber BAT im Langzeitverlauf bestätigt
  • Phase-I-Studie: Anhaltendes molekulares Ansprechen mit neuem BCR-ABL-Inhibitor Asciminib bei CML-Patienten mit T315I-Resistenzmutation
  • Patienten mit ITP sind emotional erheblich belastet
  • r/r DLBCL: Vielversprechende erste Daten zur CAR-T-Zell-Therapie mit Tisagenlecleucel in Kombination mit Ibrutinib
  • r/r FL: CAR-T-Zell-Therapie mit Tisagenlecleucel wirksam und sicher
  • Myelofibrose: Ruxolitinib-Startdosis von 10 mg 2x tägl. auch bei initial niedriger Thrombozytenzahl sicher anwendbar
  • Phase-III-Studie REACH3: Ruxolitinib bei chronischer steroidrefraktärer oder steroidabhängiger GvHD wirksamer als die beste verfügbare Therapie